Monitoring blood markers to predict treatment response in rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the levels of circulating tumor DNA (ctDNA) in patients with stage II and III rectal cancer undergoing total neoadjuvant therapy (TNT). Blood samples will be collected at three key time points: before treatment, during treatment, and after treatment to assess changes in ctDNA levels. The study will also investigate the correlation between ctDNA levels and imaging results to predict the pathological complete response to therapy. Participants will be monitored for disease-free survival over a two-year period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years and older, both genders
* Patients are diagnosed with stage II-III rectal cancer and indicated for total neoadjuvant therapy
* Biopsy FFPE sample is available at the time of diagnosis
* Patients consented to participate in the study

Exclusion Criteria:

* Stage I rectal cancer, recurrent or metastatic cancer
* Other cancer metastasis to the rectum
* Patients are indicated for chemoradiation therapy only
* Have been or are being treated for cancer
* Patients do not agree to participate in the studies.

Where it's running

• Medical Genetics Institute
  Ho Chi Minh City, Vietnam Recruiting

Study contacts

• Principal investigator: Sinh D Nguyen, PhD — Medical Genetics Institude
• Study coordinator: Lan NL Tu, PhD
• Email: lantu@genesolutions.vn
• Phone: +84888843489

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prehabilitation program for patients with rectal cancer

  This study is testing a prehabilitation program to see if it helps people with rectal cancer feel better before surgery compared to standard care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06565052

• Effects of Tislelizumab with Chemotherapy in Advanced Rectal Cancer

  This study is testing if adding a new drug called Tislelizumab to chemotherapy can help people with advanced rectal cancer have better outcomes before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Guangxi Medical University · Nanning, Guangxi · NCT06254521

• Neoadjuvant mFOLFOX with Citrus Flavonoid Tablets for YWHAB-High Locally Advanced Rectal Cancer

  In people with locally advanced rectal cancer who have high YWHAB expression, this study tests whether adding citrus flavonoid tablets to a standard mFOLFOX neoadjuvant regimen helps shrink tumors before surgery.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07176182

• Meal timing during cancer treatment for Alaska Native and American Indian patients

  This test will see if an 8-hour time-restricted eating schedule during neoadjuvant or adjuvant therapy helps Alaska Native and American Indian adults with rectal or certain breast cancers.

  Recruiting Fred Hutchinson Cancer Center · Anchorage, Alaska · NCT06802172

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.